Clinical trials: Attention-Deficit and Hyperactivity Disorder
- Condition Attention-Deficit and Hyperactivity Disorder
- Funder type Industry (pharma, biotech, devices)
ADHD
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.
- Trial name
- NCT00141063
- Testing
- Focalin XR
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Novartis
ADHD
EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")
The EndeavorRx Prospective Product Registry aims to collect real world data from participants receiving the digital therapeutic, EndeavorRx, under conditions of routine clinical practice.
- Trial name
- NCT05991167
- Testing
- EndeavorRx
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Hyperactivity Disorder
Impact of Probiotics on Children With ADHD
This study investigates WecProB (Bifidobacterium animalis subsp. lactis and Lacticaseibacillus rhamnosus) to evaluate their potential to improve symptoms and safety in children with ADHD.
- Trial name
- NCT06348121
- Testing
- Probiotic
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Wecare Probiotics Co., Ltd.
Attention Deficit Hyperactivity Disorder
Healing Minds: Biofeedback and Breathing Practices in Children and Adolescents With ADHD
The objective of this research proposal is to examine the combined effects of an integrative approach including biofeedback and breathing practices (Healing Minds) on severity of Attention Deficit Hyperactivity Disorder (ADHD) in…
- Trial name
- NCT06648252
- Testing
- Healing Minds Biofeedback and Breathing Practices Intervention
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Attention Deficit Hyperactivity Disorder (ADHD)
Effects of Probiotics on the Gut-brain Axis in Children
The effect of probiotics on the gut-brain axis in children with attention deficit hyperactivity disorder will be studied.
- Trial name
- NCT07459699
- Testing
- Probiotics
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Probi AB
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Online Neuroplasticity Training for Remediation of ADHD in Adolescent Children (ONTRAC)
This project shall rigorously evaluate the effectiveness of a novel, neuroplasticity-based internet-deliverable cognitive training program, which specifically targets the treatment of core cognitive dysfunctions observed in…
- Trial name
- NCT01772485
- Testing
- Cognitive Training, Active Control
- Where
- India
- Volunteers
- 31 people
- Sponsor
- Posit Science Corporation
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant
The purpose of this study is to determine the effects of combining AKL-T01 (with AKL-X01 symptom tracking) as adjunctive treatment to stimulant medication, and to understand the effects of AKL-T01 treatment (with AKL-X01 symptom…
- Trial name
- NCT03649074
- Testing
- AKL-T01
- Where
- 2 sites in United States
- Volunteers
- 206 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Hyperactivity Disorder, Reading Disorder
Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with…
- Trial name
- NCT00191906
- Testing
- Atomoxetine Hydrochloride
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy and safety/tolerability of 3 different dosages of JNJ-31001074 compared with placebo in adult patients with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT00880217
- Testing
- Atomoxetine 80 mg/d, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d
- Where
- 35 sites in United States
- Volunteers
- 430 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ADHD
Placebo-Controlled Comparison of Two Different Brands of Modified-Release Oral Dosage Forms Regarding Safety and Efficacy in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14
Currently two different brands of modified-release formulations are providing 50% immediate release beads/pellets and 50% extended release beads/pellets, resulting in a rapid onset and dual peak concentrations of plasma…
- Trial name
- NCT00254878
- Testing
- Methylphenidate hydrochloride
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Novartis
Attention Deficit Disorder
Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00048360
- Testing
- Extended-release bupropion hydrochloride
- Where
- 21 sites in United States
- Volunteers
- 162 people
- Sponsor
- GlaxoSmithKline
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a two-arm, parallel, randomized, double-blind, placebo-controlled Phase 4 multicenter trial to compare the whole day efficacy of atomoxetine versus placebo in children aged 6 through 12 years with…
- Trial name
- NCT00546910
- Testing
- Atomoxetine
- Where
- 16 sites in Germany
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Deep Transcranial Magnetic Stimulation (DTMS) as a Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
The aim of the study is to assess the effect of left or right high-frequency DTMS on ADHD symptoms, cognitive performance and decision-making ability of ADHD adults, and to compare this to the effect of sham DTMS on ADHD adults
- Trial name
- NCT01196910
- Testing
- treatment by HLPFC coil
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Brainsway
ADHD
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD
- Trial name
- NCT02139124
- Testing
- PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg
- Where
- 38 sites in United States, Canada
- Volunteers
- 375 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder (ADHD)
Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is develop a new assessment tool for Attention Deficit-Hyperactivity Disorder (ADHD) and to then test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls).
- Trial name
- NAT-I (NCT02407496)
- Testing
- Behavioral assessment and NAT EEG tests
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Think Now Incorporated
Attention Deficit Disorder With Hyperactivity
Short Structured Psychological Intervention for Adults With ADHD - a Randomized Controlled Trial
The purpose of this study is to evaluate the effects of a novel psychological intervention for adult ADHD through a randomized controlled trial.
- Trial name
- NCT04439422
- Testing
- Short ADHD Intervention, Self-help material with limited therapist support
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Cereb AB
Attention-Deficit/Hyperactivity Disorder
Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
To assess the pharmacokinetics of a single dose of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules under fed conditions in male or female children 4 to under 6 years of age with ADHD.
- Trial name
- PK003 (NCT02470234)
- Testing
- Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder
A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.
A 6-week double-blind study to evaluate the safety and efficacy of Quillichew extended release chewable tablets in 4-5 year old children with attention deficit hyperactivity disorder.
- Trial name
- NCT03580005
- Testing
- methylphenidate HCl ERCT
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12…
- Trial name
- NCT03088267
- Testing
- amphetamine extended-release oral suspension, 2.5 mg/mL
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Tris Pharma, Inc.